checkAd

     105  0 Kommentare Sartorius Stedim Biotech releases Universal Registration Document 2023

    Für Sie zusammengefasst
    • Sartorius Stedim Biotech releases Universal Registration Document 2023
    • Leading partner in biopharma industry
    • Financial calendar for 2024 announced

    Sartorius Stedim Biotech SA / Key word(s): Annual Results
    Sartorius Stedim Biotech releases Universal Registration Document 2023

    16-Feb-2024 / 10:00 CET/CEST


    Aubagne, February 16, 2024

    Sartorius Stedim Biotech releases Universal Registration Document 2023

    Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today. The document is available under the following link: https://ir-reports.sartorius.com/en/ssb/fy-2023


    Financial calendar 
    March 26, 2024     Annual General Meeting 
    April 18, 2024        Publication of the quarterly figures January to March 2024 
    July 19, 2024         Publication of the half-year figures January to June 2024 
    October 17, 2024   Publication of the nine-month figures January to September 2024


    A profile of Sartorius Stedim Biotech
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. Currently, more than 10,600 employees are working for customers around the globe.


    Contact
    Timo Lindemann
    External Communications 
    +49 (0)551.308.4724
    timo.lindemann@sartorius.com 


    Follow Sartorius on LinkedIn.

    Attachment

    File: Press Release


    Dissemination of a Financial Wire News, transmitted by EQS Group.
    The issuer is solely responsible for the content of this announcement.


    Language: English
    Issuer: Sartorius Stedim Biotech SA
    Avenue de Jouques
    13781 Aubagne
    France
    Phone: +33 44 284 5600
    E-mail: sartorius.presse@sartorius.com
    Internet: www.sartorius-stedim.com
    ISIN: FR0013154002
    EQS News ID: 1838423

     
    End of Announcement - EQS News Service

    1838423  16-Feb-2024 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1838423&application_name=news&site_id=wallstreet~~~257e03b8-9cbc-48b8-b6a5-ec526abf7b8e 



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    Sartorius Stedim Biotech releases Universal Registration Document 2023 Sartorius Stedim Biotech SA / Key word(s): Annual Results Sartorius Stedim Biotech releases Universal Registration Document 2023 16-Feb-2024 / 10:00 CET/CEST Aubagne, February 16, 2024Sartorius Stedim Biotech releases Universal Registration …